- Home
- NJR vs TGTX Comparison
NJR vs TGTX Comparison
Compare NJR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NJR
- TGTX
- Stock Information
- Founded
- NJR 1922
- TGTX 1993
- Country
- NJR United States
- TGTX United States
- Employees
- NJR N/A
- TGTX N/A
- Industry
- NJR Oil/Gas Transmission
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NJR Utilities
- TGTX Health Care
- Exchange
- NJR Nasdaq
- TGTX Nasdaq
- Market Cap
- NJR 4.6B
- TGTX 5.5B
- IPO Year
- NJR N/A
- TGTX 1995
- Fundamental
- Price
- NJR $46.76
- TGTX $30.92
- Analyst Decision
- NJR Hold
- TGTX Strong Buy
- Analyst Count
- NJR 6
- TGTX 5
- Target Price
- NJR $51.50
- TGTX $48.20
- AVG Volume (30 Days)
- NJR 556.9K
- TGTX 2.1M
- Earning Date
- NJR 11-19-2025
- TGTX 11-03-2025
- Dividend Yield
- NJR 4.08%
- TGTX N/A
- EPS Growth
- NJR 72.02
- TGTX N/A
- EPS
- NJR 4.10
- TGTX 2.78
- Revenue
- NJR $2,096,114,000.00
- TGTX $531,898,000.00
- Revenue This Year
- NJR $9.21
- TGTX $82.31
- Revenue Next Year
- NJR $2.29
- TGTX $49.05
- P/E Ratio
- NJR $11.37
- TGTX $11.17
- Revenue Growth
- NJR 21.02
- TGTX 100.88
- 52 Week Low
- NJR $43.46
- TGTX $25.28
- 52 Week High
- NJR $51.95
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- NJR 59.12
- TGTX 36.81
- Support Level
- NJR $45.85
- TGTX $29.80
- Resistance Level
- NJR $46.19
- TGTX $31.78
- Average True Range (ATR)
- NJR 0.73
- TGTX 1.75
- MACD
- NJR 0.25
- TGTX -0.40
- Stochastic Oscillator
- NJR 96.94
- TGTX 16.79
About NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.